Insider trade

CFO sold ~$2.5M of CORT shares in the open market

Traded Jul 15, 2026 · Filed Jul 18, 2026

Why it stands out

The money chief of Corcept Therapeutics sold $2.5M of Corcept Therapeutics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CFO$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,501,244

Shares × reported transaction price

Timing vs results

76 days after results of Apr 30, 2026, 14 days before results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.5%	−0.4%	−0.1%
30 days	+30.0%	+3.6%	+26.4%

Past results only. Not a forecast.

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.